Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES A LEATH

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1255313193
CMS profile
541051
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$35,373.26

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $26,380.59 7
GlaxoSmithKline, LLC. $7,000.00 4
Seagen Inc. $1,737.20 3
ImmunoGen, Inc. $151.92 3
Aadi Bioscience, Inc. $50.17 1
Intuitive Surgical, Inc. $33.11 2
Boston Scientific Corporation $20.27 1

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES A LEATH

NPI 1255313193 · CMS profile ID 541051

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255313193?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255313193?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255313193?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHARLES A LEATH, NPI 1255313193, CMS profile ID 541051, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1255313193?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $35,373.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $2,400.0012/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061462482 CMS
Merck Sharp & Dohme LLC $7,320.0012/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428009 CMS
Merck Sharp & Dohme LLC $150.0012/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428013 CMS
Merck Sharp & Dohme LLC $150.0012/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428015 CMS
Merck Sharp & Dohme LLC $6,100.0012/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428021 CMS
Merck Sharp & Dohme LLC $82.6412/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428011 CMS
Merck Sharp & Dohme LLC $11,863.3712/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428017 CMS
Merck Sharp & Dohme LLC $714.5812/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048428019 CMS
ImmunoGen, Inc. $15.5810/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017246867 CMS
Aadi Bioscience, Inc. $50.1710/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026485431 CMS
GlaxoSmithKline, LLC. $1,200.0010/03/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061463724 CMS
ImmunoGen, Inc. $117.5707/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017246863 CMS
ImmunoGen, Inc. $18.7707/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017246859 CMS
Intuitive Surgical, Inc. $5.0006/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055616147 CMS
Intuitive Surgical, Inc. $28.1106/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055828749 CMS
GlaxoSmithKline, LLC. $1,600.0005/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061461192 CMS
Boston Scientific Corporation $20.2704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022111699 CMS
Seagen Inc. $1,575.0004/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995809077 CMS
Seagen Inc. $127.5403/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995809119 CMS
Seagen Inc. $34.6603/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995809127 CMS
GlaxoSmithKline, LLC. $1,800.0001/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001653862 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,474.40 12
PY2020 $15,484.11 20
PY2021 $5,700.96 4
PY2022 $3,676.92 5
PY2023 $35,373.26 21
PY2024 $31,583.34 20
PY2025 $48,689.76 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $63,792.61 12
PY2024 Principal investigator $48,415.31 12
PY2023 Principal investigator $274,596.66 24
PY2022 Principal investigator $172,908.92 21
PY2021 Principal investigator $480,523.36 50
PY2020 Recipient $906.83 3
PY2020 Principal investigator $388,047.39 33
PY2019 Principal investigator $272,839.05 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11.31 12/31/2019 Covered Recipient Teaching Hospital
University Of Alabama Hospital
This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency HRD tumor status and with platinum sensitive relapsed high grade ovarian cancer Subjects should have received at least 2 prior lines of platinum based chemotherapy No dispute reported 06/30/2026 685004977
Principal investigator 1 AstraZeneca UK Limited $9.72 12/31/2019 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments No dispute reported 06/30/2026 685005615
Principal investigator 1 Seattle Genetics, Inc. $4,062.50 12/23/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822987
Principal investigator 1 TESARO, Inc. $36,170.00 11/07/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408789
Principal investigator 1 TESARO, Inc. $8,632.80 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408779
Principal investigator 1 TESARO, Inc. $422.10 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408781
Principal investigator 1 TESARO, Inc. $5,981.40 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408783
Principal investigator 1 TESARO, Inc. $20,526.00 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408785
Principal investigator 1 TESARO, Inc. $2,652.00 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408787
Principal investigator 1 Seattle Genetics, Inc. $375.00 09/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822955
Principal investigator 1 TESARO, Inc. $3,995.10 07/31/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408771
Principal investigator 1 Genentech, Inc. $1,800.00 07/11/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857127049
Principal investigator 1 TESARO, Inc. $5,066.10 07/11/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408769
Principal investigator 1 AbbVie, Inc. $3,100.00 06/18/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
M16-553 No dispute reported 06/30/2026 647601297
Principal investigator 1 TESARO, Inc. $1,820.00 06/18/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408767
Principal investigator 1 AbbVie, Inc. $24,310.00 06/10/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
M16-553 No dispute reported 06/30/2026 647601299
Principal investigator 1 Seattle Genetics, Inc. $1,011.25 05/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822951
Principal investigator 1 Seattle Genetics, Inc. $12,416.00 05/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822953
Principal investigator 1 TESARO, Inc. $2,582.10 05/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408755
Principal investigator 1 TESARO, Inc. $11,604.60 05/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408757
Principal investigator 1 TESARO, Inc. $10,642.50 05/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408759
Principal investigator 1 TESARO, Inc. $22,526.00 05/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408761
Principal investigator 1 TESARO, Inc. $3,380.00 05/14/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408747
Principal investigator 1 TESARO, Inc. $3,588.00 05/14/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408749
Principal investigator 1 Seattle Genetics, Inc. $312.50 04/25/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822949
Principal investigator 1 Seattle Genetics, Inc. $1,011.25 03/06/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer No dispute reported 06/30/2026 678822947
Principal investigator 1 TESARO, Inc. $6,287.00 02/26/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408745
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,740.22 02/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
PHASE IB AND OR II TRIAL OF LDE225 AND WEEKLY PACLITAXEL IN RECURRENT PLATINUM RESISTANT OVARIAN ADENOCARCINOMA No dispute reported 06/30/2026 640708877
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,727.00 02/14/2019 Covered Recipient Teaching Hospital
University Of Alabama Hospital
This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency HRD tumor status and with platinum sensitive relapsed high grade ovarian cancer Subjects should have received at least 2 prior lines of platinum based chemotherapy No dispute reported 06/30/2026 685004299
Principal investigator 1 TESARO, Inc. $5,115.60 02/12/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408743
Principal investigator 1 AstraZeneca UK Limited $2,793.00 02/11/2019 Covered Recipient Teaching Hospital
University Of Alabama Hospital
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments No dispute reported 06/30/2026 685005309
Principal investigator 1 Genentech, Inc. $2,750.00 02/01/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM No dispute reported 06/30/2026 857127055
Principal investigator 1 TESARO, Inc. $8,826.00 01/10/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408741
Principal investigator 1 TESARO, Inc. $2,592.00 01/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408739